Amalgamated Bank Sells 11 Shares of The Medicines Company (MDCO)

Amalgamated Bank reduced its stake in shares of The Medicines Company (NASDAQ:MDCO) by 0.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 8,946 shares of the company’s stock after selling 11 shares during the period. Amalgamated Bank’s holdings in The Medicines Company were worth $437,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Municipal Employees Retirement System of Michigan increased its stake in shares of The Medicines Company by 0.3% in the first quarter. Municipal Employees Retirement System of Michigan now owns 15,850 shares of the company’s stock valued at $775,000 after buying an additional 50 shares during the period. US Bancorp DE increased its stake in shares of The Medicines Company by 1.7% in the first quarter. US Bancorp DE now owns 3,413 shares of the company’s stock valued at $167,000 after buying an additional 58 shares during the period. Envestnet Asset Management Inc. increased its stake in shares of The Medicines Company by 5.1% in the first quarter. Envestnet Asset Management Inc. now owns 2,496 shares of the company’s stock valued at $122,000 after buying an additional 120 shares during the period. Old West Investment Management LLC increased its stake in shares of The Medicines Company by 2.5% in the first quarter. Old West Investment Management LLC now owns 10,752 shares of the company’s stock valued at $525,000 after buying an additional 259 shares during the period. Finally, Neuburgh Advisers LLC increased its stake in shares of The Medicines Company by 12.4% in the first quarter. Neuburgh Advisers LLC now owns 2,596 shares of the company’s stock valued at $127,000 after buying an additional 286 shares during the period.

The Medicines Company (NASDAQ MDCO) opened at 38.10 on Wednesday. The company’s 50 day moving average is $40.22 and its 200 day moving average is $44.14. The stock’s market cap is $2.71 billion. The Medicines Company has a 52 week low of $30.80 and a 52 week high of $55.95.

The Medicines Company (NASDAQ:MDCO) last released its earnings results on Wednesday, April 26th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($1.13) by $0.31. The firm had revenue of $24.20 million during the quarter, compared to analysts’ expectations of $37.76 million. The Medicines Company had a negative return on equity of 19.09% and a negative net margin of 91.25%. The business’s revenue was down 51.9% on a year-over-year basis. During the same period last year, the business earned ($1.03) earnings per share. Equities analysts predict that The Medicines Company will post ($5.97) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was first published by BBNS and is owned by of BBNS. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://baseballnewssource.com/markets/amalgamated-bank-sells-11-shares-of-the-medicines-company-mdco/1179676.html.

Several brokerages have issued reports on MDCO. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of The Medicines Company in a report on Saturday, March 18th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $62.00 price target on shares of The Medicines Company in a report on Wednesday, April 12th. ValuEngine downgraded shares of The Medicines Company from a “sell” rating to a “strong sell” rating in a report on Saturday, May 20th. Cowen and Company upped their price target on shares of The Medicines Company from $39.00 to $61.00 and gave the company an “outperform” rating in a report on Wednesday, April 19th. Finally, Oppenheimer Holdings, Inc. began coverage on shares of The Medicines Company in a report on Monday, May 22nd. They issued a “market perform” rating and a $50.00 price target on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $54.40.

The Medicines Company Company Profile

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Institutional Ownership by Quarter for The Medicines Company (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with our FREE daily email newsletter.

 


Latest News

Veteran Pitcher Bartolo Colon Considering Retirement
Veteran Pitcher Bartolo Colon Considering Retirement
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Todd Frazier Trade to Boston Appears to Be Decided
Todd Frazier Trade to Boston Appears to Be Decided
Chicago White Sox Continue Rebuild Without Jose Quintana
Chicago White Sox Continue Rebuild Without Jose Quintana
Mike Trout Returns from Injury With Single and Stole Base
Mike Trout Returns from Injury With Single and Stole Base


Leave a Reply

 
© 2006-2017 BBNS.